COST-EFFECTIVENESS OF DAPAGLIFLOZIN PLUS STANDARD TREATMENT COMPARED TO STANDARD TREATMENT FOR THE MANAGEMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN COLOMBIA

被引：0
|
作者：
Rojas, Gil Y. [1 ]
Lasalvia, P. [1 ]
Pena, Garcia A. A. [2 ]
机构：
[1] NeuroEconomix, Bogota, Colombia
[2] Hosp San Ignacio, Bogota, Colombia
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB161
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [1] Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia
    Gil-Rojas, Yaneth
    Lasalvia, Pieralessandro
    Garcia, Angel
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 655 - 663
  • [2] Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
    Yao, Younan
    Zhang, Rongcheng
    An, Tao
    Zhao, Xinke
    Zhang, Jian
    [J]. ESC HEART FAILURE, 2020, 7 (06): : 3582 - 3592
  • [3] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    [J]. JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [4] Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia
    Lasalvia, Pieralessandro
    Vasquez, M. Eliana C.
    Alvarez, Jose Javier Arango
    Garcia-Padilla, Paola
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024,
  • [5] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    [J]. JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
  • [6] Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    V. Nguyen, Hai
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 376 : 83 - 89
  • [7] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    [J]. CIRCULATION, 2020, 142
  • [8] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [9] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF CHRONIC SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE NETHERLANDS
    Kvamme, I
    de Graaf, G.
    Nekerman, S.
    Gijsbers, S.
    Wester, V
    Hoogendoorn, M.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S170 - S170
  • [10] COST-EFFECTIVENESS OF USING DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A PHARMACOECONOMIC MODEL ANALYSIS
    Cavusoglu, Y.
    Demir, O.
    Dinc, M.
    Ozsoy, A.
    Erdogan, A.
    Ozer, S.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S66 - S66
12345